J.Molner AS (OTSE:MOLNR) Capex-to-Revenue : 4.67 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is J.Molner AS Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

J.Molner AS's Capital Expenditure for the six months ended in Dec. 2023 was €-1.62 Mil. Its Revenue for the six months ended in Dec. 2023 was €0.35 Mil.

Hence, J.Molner AS's Capex-to-Revenue for the six months ended in Dec. 2023 was 4.67.

J.Molner AS Capex-to-Revenue Historical Data

The historical data trend for J.Molner AS's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

J.Molner AS Capex-to-Revenue Chart

J.Molner AS Annual Data

Trend

Dec21

Dec22

Dec23

Capex-to-Revenue

0.51

2.77

J.Molner AS Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Revenue	-	-	-	0.34	4.67

Competitive Comparison of J.Molner AS's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

J.Molner AS's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where J.Molner AS's Capex-to-Revenue falls into.

J.Molner AS Capex-to-Revenue Calculation

J.Molner AS's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-1.712)	/	0.618
	=	2.77

J.Molner AS's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-1.619)	/	0.347
	=	4.67

J.Molner AS (OTSE:MOLNR) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

J.Molner AS Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of J.Molner AS's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

J.Molner AS (OTSE:MOLNR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » J.Molner AS (OTSE:MOLNR) » Definitions » Capex-to-Revenue

Traded in Other Exchanges

N/A

Address

Akadeemia tee 21/5, Harju maakond, Tallinn, EST, 12618

Website

https://www.jmolner.com

J.Molner AS is an Estonia-based company. The company is engaged in research and development in the field of biotechnology. The activities of the Company are divided into two fields: 1) Chemistry analytical and development services for third parties; 2) Development of the Company's own line of generic pharmaceuticals.

J.Molner AS (OTSE:MOLNR) Headlines

No Headlines